The sudden surge in demand for semaglutide and tirzepatide has left many patients searching for alternatives. We break down the clinical data on compounded alternatives and help you navigate current supply constraints.
Understanding the Supply Chain
The GLP-1 medication shortage stems from unprecedented demand growth. Novo Nordisk and Eli Lilly have both expanded manufacturing, but production capacity hasn’t kept pace with prescriptions increasing 300% year-over-year.
Compounded Alternatives
Compounded semaglutide has emerged as a viable alternative for many patients. These medications are prepared by licensed 503B compounding pharmacies under FDA oversight.
“Compounded alternatives can be a legitimate bridge therapy during supply constraints, provided they come from properly licensed facilities.” — Dr. Sarah Chen
What to Look For
When evaluating compounded options:
- Verify the pharmacy’s 503B license — this ensures FDA oversight
- Check for third-party testing — reputable providers publish purity results
- Avoid “salt form” variations — the FDA has cautioned against certain formulations
- Confirm proper cold-chain shipping — semaglutide requires temperature control